The risk and management of anaphylaxis in the setting of immunotherapy
Author: Lieberman, Phil
Source: American Journal of Rhinology & Allergy, Volume 26, Number 6, November/December 2012 , pp. 469-474(6)
Publisher: OceanSide Publications, Inc
Abstract:Background: Anaphylactic events due to immunotherapy are probably not completely preventable. There is always an inherent risk surrounding the administration of an allergen to an individual who is sensitized to the substance administered. Methods: There are, however, effective measures to reduce the risk of these events, and to optimize the assurance of a good outcome in the face of such an event. Results: Of prime importance in preventing these episodes is the regular assessment of the patient's health status, especially in regard to asthma, and the careful attention to the prevention of dosing errors. Conclusion: Of equal importance, in regard to assuring a good outcome should such an event occur, are the rapid recognition of symptoms and the immediate injection of epinephrine, the drug of choice for the treatment of any episode of anaphylaxis.
Document Type: Research article
Publication date: 2012-11-01
- The American Journal of Rhinology & Allergy, is a peer reviewed, scientific publication committed to expanding knowledge and publishing the best clinical and basic research within the fields of Rhinology & Allergy. Its focus is to publish information which contributes to improved quality of care for patients with nasal and sinus disorders. Its primary readership consists of otolaryngologists, allergists, and plastic surgeons. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
Previously published as American Journal of Rhinology, the journal is indexed in Thomson Reuters Web of Science and Science Citation Index, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Reprint Requests
- ingentaconnect is not responsible for the content or availability of external websites